Restoring vessel function by normalizing tumor stroma has been evaluated in preclinical models through targeting angiotensin signaling with anti-hypertensive agents (125) or inhibiting SDF-1/CXCR4 (86) which can target CAFs and collagen/hyaluronan to decompress tumor vessels and improve perfusion and effect of the ICB. The gene discussed is CXCL12; the disease is neoplasm.